-
1
Advances in sodium-glucose transporter protein 2 inhibitors and tumors
Published 2025-02-01Subjects: “…SGLT2i…”
Get full text
Article -
2
A study on the pharmacovigilance of various SGLT-2 inhibitors
Published 2025-01-01Subjects: “…SGLT2i…”
Get full text
Article -
3
Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
Published 2022-06-01Subjects: Get full text
Article -
4
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
Published 2025-01-01Subjects: Get full text
Article -
5
Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
Published 2025-12-01Subjects: “…SGLT2i…”
Get full text
Article -
6
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
Published 2024-12-01Subjects: Get full text
Article -
7
Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice
Published 2024-04-01Subjects: Get full text
Article -
8
Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analys...
Published 2025-01-01Subjects: “…SGLT-2i…”
Get full text
Article -
9
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
Published 2024-11-01Subjects: Get full text
Article -
10
Incidence of hyperkalemia RAASi and SGLT-2i treatment in individuals with diabetic kidney disease: a systematic review and network meta-analysis
Published 2025-01-01Subjects: Get full text
Article -
11